hTERT peptide-based vaccine- Invectys

Drug Profile

hTERT peptide-based vaccine- Invectys

Alternative Names: hTERT prptide vaccine- Invectys; Human telomerase reverse transcriptase peptide-based vaccine - Invectys; UCPVax

Latest Information Update: 04 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Invectys
  • Developer Invectys; Regional and University Hospital of Besancon
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 May 2016 Phase-I/II clinical trials in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in France (SC) (NCT02818426)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top